favicon 96 vfldSA3ca    Facebook Icon    Twitter icon

Latest Publication

In-silico study of toxicokinetics and disease association of chemicals present in smokeless tobacco products.
Bhartiya D, Kumar A, Kaur J, Kumari S, Sharma AK, Sinha DN, Singh H, Mehrotra R.
Regul Toxicol Pharmacol. 2018 Mar 2;95:8-16. doi: 10.1016/j.yrtph.2018.03.002., PMID: 29505798

Children could keep the healthcare community on its toes.
Rooh S, Asthana A, Satyanarayana L., BMJ. 2018 Feb 9;360:k606. doi: 10.1136/bmj.k606. PMID: 29438967

Harnessing genomics to improve outcomes for women with cancer in India: key priorities for research.
Sundar S, Singh P, Frampton J, Trimble E,Rajaraman P, Mehrotra R, Hariprasad R, Maitra A, Gill P, Suri V, Srinivasan R, Singh G, Thakur J.S, Dhillon P, Cazier J-B
The Lancet Oncology. 2018; Volume 19, No. 2, e102–e112

Population-based cancer screening programmes in low-income and middle-income countries: regional consultation of the International Cancer Screening Network in India.
Sivaram S, Majumdar G, Perin D, Nessa A, Broeders M, Lynge E, Saraiya M, Segnan N, Sankaranarayanan R, Rajaraman P, Trimble E, Taplin S, Rath GK, Mehrotra R
The Lancet Oncology. 2018; Volume 19, No. 2, e113–e122

Efficacy of Complementary Therapies in the Quality of Life of Breast Cancer Survivors.
Zaidi S, Hussain S, Verma S, Veqar Z, Khan A, Nazir SU, Singh N, Moiz JA, Tanwar P, Srivastava A, Rath GK, Mehrotra R.
Front Oncol. 2018 Jan 11;7:326. doi: 10.3389/fonc.2017.00326. eCollection 2017. Review., PMID: 29376027

Risk of coronary heart disease among smokeless tobacco users: results of systematic review and meta-analysis of global data
Ruchika Gupta, Sanjay Gupta, Shashi Sharma, Dhirendra N Sinha, Ravi Mehrotra
Nicotine & Tobacco Research, nty002, https://doi.org/10.1093/ntr/nty002

Nations within a nation: variations in epidemiological transition across the states of India, 1990-2016 in the Global Burden of Disease Study.
India State-level Disease Burden Initiative Collaborators. Lancet. 2017 Nov 13. pii: S0140-6736(17)32804-0. doi: 10.1016/S0140-6736(17)32804-0. [Epub ahead of print], PMID: 29150201

Human papillomavirus vaccine for cancer cervix prevention: Rationale & recommendations for implementation in India.

Kaur P, Mehrotra R, Rengaswamy S, Kaur T, Hariprasad R, Mehendale S.M, Rajaraman P, Rath G.K, Bhatla N, Krishnan S, Nayyar A & Swaminathan S..

Indian J Med Res 146, August 2017, pp 153-157 Quick Response Code: DOI: 10.4103/ijmr.IJMR_1906_16

Cancer cervix is among the leading causes of death with age standardized incidence of 22 per 100,000 women in India. Human Papilloma Virus (HPV) vaccine is one of the recommended interventions for cervical cancer prevention. There is ample evidence regarding immunogenicity, efficacy and safety profile of two HPV vaccines available in India. Quadrivalent vaccine protects against 4 HPV types (6,11,16 and 18) and bivalent vaccine protects against 2 HPV types (16, 18). Global Advisory Committee on Vaccine Safety (WHO) released statement regarding the safety of vaccine after administration of more than 200 million doses worldwide since 2006. A sustainable mode of financing should be identified to ensure long term continuity of programs. School based approach or combination of approaches can be used to achieve high coverage. A system should be established to monitor adverse events.

Association of SNPs/haplotypes in promoter of TNF A and IL-10 gene together with life style factors in prostate cancer progression in Indian population.
Bandil K, Singhal P, Dogra A, Rawal SK, Doval DC, Varshney AK, Bharadwaj M.
Inflamm Res. 2017 Dec;66(12):1085-1097.

Is there a role of personalized cancer treatment in Prostate Cancer? According to this study, TNF A −238G>A and IL-10 −1082A>G, −819C>T and −592C>A may be associated with the development of prostate cancer and Benign Prostatic Hypertrophy. The authors also noticed higher frequency of TNF A and IL-10 risk haplotypes in smokers and alcohol users. Interestingly, IL-10 risk haplotype was positively associated with aggressiveness of tumor. This information can be used for the early diagnosis of disease and to improve tissue-specific treatment’s efficacy which will be moving ultimately towards the discovery of personalized therapy.

Stemming the Wave of Cervical Cancer: Human Papillomavirus Vaccine Introduction in India
Authors: Ravi Mehrotra, Roopa Hariprasad, Preetha Rajaraman, Rajesh Grover, Soumya Swaminathan, Vini Mahajan and Prabhdeep Kaur

Optimizing secondary prevention of cervical cancer: Recent advances and future challenges.
Authors: Ogilvie G, Nakisige C, Huh WK, Mehrotra R, Franco EL and Jeronimo J.
PMID: 28691338 

Non Communicable Disease Risk Factors and their Trends in India
Authors: Suzanne Nethan, Dhirendra Sinha and Ravi Mehrotra

Management algorithms for cervical cancer screening and precancer treatment for resource-limited settings
Authors: Basu P, Meheus F, Chami Y, Hariprasad R and Zhao F, Sankaranarayanan R.
PMID: 28691336 DOI: 10.1002/ijgo.12183

Cervical Cancer Screening in Resource-Constrained Countries: Current Status and Future Directions
Authors: Ruchika Gupta, Sanjay Gupta, Ravi Mehrotra and Pushpa Sodhani

Bacterial Vaginosis and Cervical Intraepithelial Neoplasia: Is there an Association or is Co-Existence Incidental?
Authors: Pushpa Sodhani, Sanjay Gupta, Ruchika Gupta and Ravi Mehrotra